Final 3‐year clinical outcomes following transcatheter aortic valve implantation with a supra‐annular self‐expanding repositionable valve in a real‐world setting: Results from the multicenter FORWARD study

Objectives The Evolut R FORWARD study confirmed safety and effectivenesss of the Evolut R THV in routine clinical practice out to 1 year. Herein, we report the final 3‐year clinical follow up of the FORWARD study. Background Transcatheter aortic valve replacement (TAVR) is a proven alternative to surgery in elderly patients with symptomatic severe aortic stenosis. Long‐term clinical outcome data with the Evolut R platform are scarce. Methods...